{
    "organizations": [],
    "uuid": "fb9c5119fc0bf34d327734522e57636e424acd20",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aerie-pharmaceuticals-reports-q4-a/brief-aerie-pharmaceuticals-reports-q4-adjusted-loss-per-share-1-38-idUSASB0C828",
    "ord_in_thread": 0,
    "title": "BRIEF-Aerie Pharmaceuticals Reports Q4 Adjusted Loss Per Share $1.38",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 28 (Reuters) - Aerie Pharmaceuticals Inc:\n* AERIE PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE AND 2018 GUIDANCE\n* Q4 ADJUSTED LOSS PER SHARE $1.38 * Q4 GAAP LOSS PER SHARE $1.60 * ‍EXPECTS CASH BURN FOR FULL YEAR 2018 IN RANGE OF $200 MILLION TO $210 MILLION​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-01T05:06:00.000+02:00",
    "crawled": "2018-03-01T21:28:49.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "aerie",
        "pharmaceutical",
        "inc",
        "aerie",
        "pharmaceutical",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "provides",
        "business",
        "update",
        "guidance",
        "q4",
        "adjusted",
        "loss",
        "per",
        "share",
        "q4",
        "gaap",
        "loss",
        "per",
        "share",
        "cash",
        "burn",
        "full",
        "year",
        "range",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}